Giampaolo Bianchini from the IRCCS Ospendale San Raffaele, Milano, Lombardy, Italy, discusses why overall survival is considered the 'gold standard' endpoint for research into cancer agents and what this means for patients with metastatic breast cancer.
1. What is the clinical definition of overall survival? (0:04)
2. Why is overall survival considered by many the ‘gold standard’ endpoint for research into cancer agents (0:44)
3. Could you talk us through the use of eribulin in metastatic breast cancer? (1:33)
4. How has the landscape for overall survival changed for patients with metastatic breast cancer? (2:30)
5. How do you believe the treatment landscape will evolve for patients with metastatic breast cancer in the near future? (3:37)
Adverse Events in Clinical Studies (4:11)
Prescribing information (5:05)
Support: This film has been initiated and funded by Eisai.
Filmed at the San Antonio Breast Cancer Symposium (SABCS), 40 Year Anniversary, San Antonio, Texas, USA, December 2017.